Biogen_Logo_Standard-rgb_R.jpg
Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases
May 01, 2019 07:30 ET | Biogen Inc.
Data demonstrate that pre-symptomatic infants with SMA treated with SPINRAZA® (nusinersen) over three years achieved motor milestones that are more consistent with normal childhood...
Innodem Neurosciences Receives 1 Million Dollars in Funding to Give a Voice to Voiceless Patients
February 19, 2019 15:49 ET | Innodem Neurosciences
MONTREAL, Feb. 19, 2019 (GLOBE NEWSWIRE) -- CENTECH’s Innodem Neurosciences, a Montreal-based start-up that spun-out of McGill University’s Montreal Neurological Institute and Hospital (The NEURO)...
Innodem Neurosciences reçoit un million de dollars de financement afin de donner une voix aux patients privés de la parole
February 19, 2019 15:49 ET | Innodem Neurosciences
MONTRÉAL, 19 févr. 2019 (GLOBE NEWSWIRE) -- Innodem Neurosciences, jeune entreprise issue de l’Institut et hôpital neurologique de Montréal (Le Neuro) de l’Université McGill et membre de...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Publications on AAV Gene Therapy Approach to Treating Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD) in the Journal Molecular Therapy Nucleic Acids
February 15, 2019 07:24 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 15, 2019 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
biologlogo.jpg
ALS related metabolic pathway discovered by Sheffield scientists using Biolog technology
February 13, 2019 00:15 ET | Biolog, Inc.
SHEFFIELD, United Kingdom and HAYWARD, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- Researchers at the University of Sheffield have identified a new pathway that is disrupted in amyotrophic lateral...
cloudmedxlogo.png
Barrow Neurogolical Institute (Dignity Health) Collaborates With CloudMedx AI Platform to Create New Predictive Analytics Tools for the Management of Patients With Amyotrophic Lateral Sclerosis (ALS)
January 03, 2019 16:07 ET | CloudMedx Inc.
PALO ALTO, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- CloudMedx, a healthcare AI company that provides real time and actionable insights to the healthcare industry, today announced its collaboration...
Biogen_Logo_Standard-rgb_R.jpg
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
December 06, 2018 07:30 ET | Biogen Inc.; Ionis Pharmaceuticals, Inc.
Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067Biogen plans to advance BIIB067 to a pivotal clinical studyBiogen paid Ionis Pharmaceuticals a $35 million...
Cytokinetics_Logo_RGB (1).jpg
Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS
November 27, 2018 07:30 ET | Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in FORTITUDE-ALS (Functional Outcomes in...
TMlogo.jpg
Q Therapeutics Receives Orphan Drug Designation for Transverse Myelitis
September 26, 2018 06:00 ET | Q Therapeutics, Inc.
FDA DESIGNATION WOULD PROVIDE 7 YEARS OF MARKET EXCLUSIVITY UPON MARKET APPROVAL OF Q-CELLS® SALT LAKE CITY, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage...
logo.png
Orphazyme announces enrollment of first patient in Phase III clinical trial of arimoclomol for ALS
August 10, 2018 12:19 ET | ORPHAZYME A/S
Orphazyme A/SCompany announcement                                                                                                                   No....